Assembly Biosciences announces pricing of $100M offering

Assembly Biosciences, Inc. (Nasdaq: ASMB) has announced the pricing of a $175 million equity offering, which includes the issuance of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, along with accompanying Class A and Class B warrants to purchase up to 6,632,660 shares of common stock. The combined price per share of common stock and accompanying warrants is $19.60 for shares and $19.599 for pre-funded warrants. The offering is expected to close on August 11, 2025, subject to customary conditions.

The offering includes participation from both new and existing investors, such as Commodore Capital, Blackstone Multi-Asset Investing, and RA Capital Management. Additionally, Gilead Sciences, Inc. has agreed to purchase 2,295,920 shares of common stock and accompanying warrants in a private placement at the same offering price.

The company plans to use the net proceeds from the offering and private placement for general corporate purposes. Guggenheim Securities is serving as lead book-running manager, while Mizuho is also acting as a book-running manager.

This follows a previous $12.6 million equity financing in June 2024, which included investments from Armistice Capital and Gilead, supporting the advancement of Assembly Bio’s antiviral portfolio and extending its cash runway into Q1 2026.